The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on March 26 2026, recommending that Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) be expanded to treat acquired hypothalamic obesity (HO) in adults and children aged four and older. The decision follows the company’s FDA approval of the same indication on March 19 2026 and represents a key regulatory milestone that paves the way for formal European Commission approval.
The expanded label would add an estimated 10,000 patients to Rhythm’s addressable market in the EU, a figure that aligns with the company’s own estimate that roughly 10,000 people in the United States and Europe live with acquired HO. The additional patient base could provide a new revenue stream that helps offset Rhythm’s high cash burn and supports the launch of its broader hypothalamic obesity program.
The CHMP opinion was based on robust clinical data from the Phase III Transcend trial, which showed a 15.8% reduction in body‑mass index at 52 weeks compared with a 2.6% increase in the placebo group, translating to a placebo‑adjusted 18.4% BMI reduction. The data, combined with strong manufacturing quality, gave regulators confidence in setmelanotide’s safety and efficacy profile.
"The positive CHMP opinion with a broad label following closely upon last week's FDA approval validates the quality of the data which supports our filings in acquired HO and further confirms our global approach to drug development," said David Meeker, M.D., Chairman, President and CEO of Rhythm. "Acquired HO represents a significant unmet medical need across geographies and a unique opportunity for Rhythm which we are well positioned to execute on.",
Professor Hanneke van Santen, M.D., Ph.D., of the Prinses Máxima Center and Wilhelmina Children’s Hospital in Utrecht, explained that acquired hypothalamic obesity is a devastating neuroendocrine disease characterized by reduced energy expenditure, hyperphagia and accelerated, sustained weight gain resulting from physical injury or structural abnormality of the hypothalamus. "This disease condition is driven by impairment of MC4R pathway signaling and other hypothalamic functional damage, making it exceptionally difficult to manage with existing approaches," she said.
Rhythm’s financial position provides a solid foundation for pursuing the expanded indication. The company reported $57.3 million in net product revenue for Q4 2025 and $194.8 million for the full year, and held $388.9 million in cash, cash equivalents and short‑term investments at the end of 2025, giving it a runway of at least 24 months.
The EMA positive opinion strengthens Rhythm’s competitive moat in the rare obesity space, where it is the sole approved MC4R agonist. While the broader obesity market is dominated by GLP‑1 agonists such as semaglutide and tirzepatide, setmelanotide’s first‑in‑class mechanism targets a highly specific patient population that has limited treatment options, positioning Rhythm for sustained growth in a niche but high‑need segment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.